Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

Leon Berard , Lyon, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Lyon
Treatments:ChemotherapyHospital:Leon Berard
Drugs:Journal:Link
Date:Aug 2003

Description:

Patients: This Phase II randomized study involved 54 patients with hormone refractory metastatic prostate cancer. Patients were divided into two groups: Group 1 with 26 patients and Group 2 with 28 patients. For patients in Group 1, the median age was 68 and the median PSA was 85.

Treatment: For patients in Group 1, the treatment consisted of the chemotherapy drug oxaliplatin (eloxatin).

Toxicity: For patients in Group 1, grade 3-4 toxicities included anemia, neutropenia, asthenia, and neurosensory.

Results: For patients in Group 1, the median overall survival was 9.4 months.

Support: The study was supported by a grant from Sanofi-Synthelabo. This company manufactures oxaliplatin (eloxatin).

Correspondence: Dr. S. Mackenzie





Back